Administrative core

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 3P01AI165077-01S1

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2021
    2024
  • Known Financial Commitments (USD)

    $240,552
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    PROFESSOR YOSHIHIRO KAWAOKA
  • Research Location

    United States of America
  • Lead Research Institution

    UNIVERSITY OF WISCONSIN-MADISON
  • Research Priority Alignment

    N/A
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

SUMMARY The Administrative Core of the Pan-Coronavirus Vaccine (PanCoVac) Consortium is responsible for organizing and overseeing all administrative aspects of the research program. The overall goal of this research program is to develop and evaluate novel antigens to elicit broadly protective antibodies against multiple coronaviruses. This goal will be achieved through coordination with two Research Projects in the consortium. As Principal Investigator of this program and the Administrative Core Lead, Dr. Yoshihiro Kawaoka will be responsible for managing, coordinating and supervising all program activities. To ensure program success, the Administrative Core will (1) provide a management and staffing plan that brings together a team with the appropriate expertise to perform the proposed research and provides a framework for effective team management and coordination and (2) provide and implement an organizational and administrative strategy that facilitates team collaboration to achieve proposed goals and fulfill program requirements in a timely manner.